Erik G. Stilp, MD, FACC, RPVI

Stenting the Popliteal Artery

09/05/2019

Erik G. Stilp , MD, FACC, RPVI;

I hesitate to stent in the P2 and P3 segments of the popliteal, but the LifeStent Vascular Stent System (BD) is a nice option in those places, based off the level 1, rigorous ETAP trial data(1) (Endovascular Treatment of Atherosclerotic...

I hesitate to stent in the P2 and P3 segments of the popliteal, but the LifeStent Vascular Stent System (BD) is a nice option in those places, based off the level 1, rigorous ETAP trial data(1) (Endovascular Treatment of Atherosclerotic...

I hesitate to stent in the P2...

09/05/2019

Cath Lab Digest

Review

The Link Between Vasculogenic Erectile Dysfunction, Coronary Artery Disease, and Peripheral Artery Disease: Role of Metabolic Factors and Endovascular Therapy

06/04/2013

Erik G. Stilp , MD, FACC, RPVI;

Stephanie M. Meller , BA;

Charles N. Walker , MD;

Carlos Mena-Hurtado , MD;

Recently investigated treatments for erectile dysfunction (ED) are reviewed along with an overview of the anatomy of normal erectile physiology and the pathophysiology of ED.

Recently investigated treatments for erectile dysfunction (ED) are reviewed along with an overview of the anatomy of normal erectile physiology and the pathophysiology of ED.

Recently investigated treatments...

06/04/2013

Journal of Invasive Cardiology

Shockwave at ISET

Sponsored Video

Treating Calcified BTK Disease with Shockwave IVL

07/02/2024

Erik G. Stilp , MD, FACC, RPVI;

Nicolas Mouawad , MD, MPH, MBA, FSVS, FRCS, FACS;

Elizabeth Genovese , MD, MS, FACS, RPVI;

Kumar Madassery , MD;

Drs. Erik Stilp, Nicolas Mouawad, Liz Genovese and Kumar Madassery discuss their best practices when treating patients with below-the-knee disease.

Drs. Erik Stilp, Nicolas Mouawad, Liz Genovese and Kumar Madassery discuss their best practices when treating patients with below-the-knee disease.

Drs. Erik Stilp, Nicolas...

07/02/2024

Vascular Disease Management

Featured CME Course

Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes

Upcoming Events

February 2 ⁠–⁠ February 5

February 7 ⁠–⁠ February 9

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

March 22 ⁠–⁠ March 23

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

WoundCon

May 1 ⁠–⁠ May 3

See Full Calendar